• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对一种对放线菌素 A 的苯甲酰芥末衍生物（FCE 24517）具有抗性的 LoVo 亚系的特性研究。

Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517).

作者信息

Capolongo L, Melegaro G, Broggini M, Mongelli N, Grandi M

机构信息

Farmitalia Carlo Erba, Research Center, Oncology Department, Nerviano, Milano, Italy.

出版信息

Br J Cancer. 1993 Nov;68(5):916-9. doi: 10.1038/bjc.1993.454.

DOI:10.1038/bjc.1993.454
PMID:8105866
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1968750/
Abstract

Human colon adenocarcinoma cells (LoVo) resistant to the new antitumor agent FCE 24517 [benzoyl-mustard derivative of distamycin A] (LoVo/24517) are resistant to the selecting agent and related molecules as well as to vinblastine, with marginal or no resistance to other antitumour drugs. Treatment with verapamil, tamoxifen, nicergoline or cyclosporin A only partially restores the activity of FCE 24517 against LoVo/24517 cells. Such results suggest that resistance mechanisms possible specific for this class of compounds are operating.

摘要

对新型抗肿瘤药物FCE 24517[放线菌素A的苯甲酰-氮芥衍生物]具有抗性的人结肠腺癌细胞(LoVo)(LoVo/24517)，对选择剂及相关分子以及长春碱具有抗性，对其他抗肿瘤药物仅有轻微抗性或无抗性。用维拉帕米、他莫昔芬、尼麦角林或环孢素A处理只能部分恢复FCE 24517对LoVo/24517细胞的活性。这些结果表明，可能存在针对这类化合物的特异性抗性机制在起作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5b4/1968750/49afee17a538/brjcancer00201-0093-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5b4/1968750/49afee17a538/brjcancer00201-0093-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5b4/1968750/49afee17a538/brjcancer00201-0093-a.jpg

相似文献

1
Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517).对一种对放线菌素 A 的苯甲酰芥末衍生物（FCE 24517）具有抗性的 LoVo 亚系的特性研究。
Br J Cancer. 1993 Nov;68(5):916-9. doi: 10.1038/bjc.1993.454.
2
Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies.
Int J Cancer. 1993 Jan 21;53(2):308-14. doi: 10.1002/ijc.2910530223.
3
Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A.新型放线菌素D苯甲酰芥子气类似物FCE 24517的生物学特性
Br J Cancer. 1991 Dec;64(6):1047-50. doi: 10.1038/bjc.1991.463.
4
The effects of a benzoic acid mustard derivative of distamycin A (FCE 24517) and related minor groove-binding distamycin analogues on the activity of major groove-binding alkylating agents.双氢链霉素A的苯甲酸芥子衍生物（FCE 24517）及相关的小沟结合双氢链霉素类似物对大沟结合烷化剂活性的影响。
Biochem Pharmacol. 1993 Feb 9;45(3):619-26. doi: 10.1016/0006-2952(93)90135-j.
5
Decreased tyrosine phosphorylation in tumour cells resistant to FCE 24517 (tallimustine).对FCE 24517（他利莫司汀）耐药的肿瘤细胞中酪氨酸磷酸化减少。
Br J Cancer. 1995 Dec;72(6):1504-8. doi: 10.1038/bjc.1995.537.
6
FCE 24517-resistant MCF-7 human breast cancer cell line: selection and characterization.
Anticancer Drugs. 1999 Aug;10(7):663-9. doi: 10.1097/00001813-199908000-00006.
7
DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin.新型抗肿瘤药物他林莫司汀（FCE 24517，一种偏端霉素的苯甲酰氮芥衍生物）引起的DNA序列特异性腺嘌呤烷基化。
Nucleic Acids Res. 1995 Jan 11;23(1):81-7. doi: 10.1093/nar/23.1.81.
8
Cytotoxic and antitumor activity of MEN 10710, a novel alkylating derivative of distamycin.MEN 10710（一种新型的偏端霉素烷基化衍生物）的细胞毒性和抗肿瘤活性
Anticancer Drugs. 1997 Oct;8(9):845-52. doi: 10.1097/00001813-199710000-00005.
9
Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line.维拉帕米或mdr1反义寡脱氧核苷酸对多药耐药性的调节并不会改变耐多药人结肠癌（LoVo）细胞系对淋巴因子激活的杀伤细胞的高敏感性。
Int J Cancer. 1990 Oct 15;46(4):727-32. doi: 10.1002/ijc.2910460429.
10
Distamycin-A derivatives potentiate tumor-necrosis-factor activity via the modulation of tyrosine phosphorylation.放线菌素A衍生物通过调节酪氨酸磷酸化增强肿瘤坏死因子活性。
Int J Cancer. 1997 Sep 4;72(5):810-4. doi: 10.1002/(sici)1097-0215(19970904)72:5<810::aid-ijc17>3.0.co;2-c.

引用本文的文献

1
Tallimustine in advanced previously untreated colorectal cancer, a phase II study.替莫司汀治疗既往未接受过治疗的晚期结直肠癌：一项II期研究
Br J Cancer. 1996 Mar;73(6):803-4. doi: 10.1038/bjc.1996.140.
2
Decreased tyrosine phosphorylation in tumour cells resistant to FCE 24517 (tallimustine).对FCE 24517（他利莫司汀）耐药的肿瘤细胞中酪氨酸磷酸化减少。
Br J Cancer. 1995 Dec;72(6):1504-8. doi: 10.1038/bjc.1995.537.

本文引用的文献

1
Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies.
Int J Cancer. 1993 Jan 21;53(2):308-14. doi: 10.1002/ijc.2910530223.
2
Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues.他莫昔芬及其他三苯乙醇类似物逆转P388小鼠白血病细胞对阿霉素的获得性耐药
Cancer Res. 1984 Oct;44(10):4392-5.
3
Reversal of adriamycin resistance by verapamil in human ovarian cancer.维拉帕米逆转人卵巢癌对阿霉素的耐药性。
Science. 1984 Jun 1;224(4652):994-6. doi: 10.1126/science.6372095.
4
Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin.一株对阿霉素耐药的人结肠腺癌细胞系的分离与鉴定
Br J Cancer. 1986 Sep;54(3):515-8. doi: 10.1038/bjc.1986.206.
5
Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129.环孢素A增强柔红霉素对艾氏腹水癌和小鼠肝癌129的疗效。
Cancer Res. 1987 Dec 1;47(23):6216-9.
6
Isolation and expression of a complementary DNA that confers multidrug resistance.一种赋予多药耐药性的互补DNA的分离与表达。
Nature. 1986;323(6090):728-31. doi: 10.1038/323728a0.
7
The molecular origin of DNA-drug specificity in netropsin and distamycin.纺锤菌素和偏端霉素中DNA-药物特异性的分子起源。
Proc Natl Acad Sci U S A. 1985 Mar;82(5):1376-80. doi: 10.1073/pnas.82.5.1376.
8
Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements.偏端霉素抑制OTF-1和NFE-1转录因子与其保守DNA元件的结合。
Nucleic Acids Res. 1989 Feb 11;17(3):1051-9. doi: 10.1093/nar/17.3.1051.
9
Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives.
J Med Chem. 1989 Apr;32(4):774-8. doi: 10.1021/jm00124a008.
10
Selective DNA interaction of the novel distamycin derivative FCE 24517.新型偏端霉素衍生物FCE 24517的选择性DNA相互作用
Cancer Res. 1991 Jan 1;51(1):199-204.